Commercial Court of Lyon Approves Poxel's Recovery Plan

Poxel SA has announced its exit from judicial reorganization proceedings following the approval of its recovery plan by the Commercial Court of Lyon. This conclusion marks the end of a period of financial observation that began in August 2025. The sanctioned recovery plan allows Poxel to focus on its commercial expansion, particularly for its products like Imeglimin and PXL770.

The plan involves establishing partnerships for Imeglimin's commercialization in Asia, with a focus on China, and promoting PXL770 for ADPKD. Poxel aims to enhance operational efficiency by minimizing administrative costs and optimizing its workforce strategy.

Financially, the plan includes settling outstanding debts with Orbimed and IPF, with parts of the IPF debt converted into shares. Additionally, Poxel's financial foundation will be bolstered by a €5 million equity line from IRIS and a capital increase backed by IPF and other stakeholders.